A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer.
BACKGROUND: There is a continued need to develop more effective cancer immunotherapy strategies. Exosomes, cell-derived lipid vesicles that express high levels of a narrow spectrum of cell proteins represent a novel platform for delivering high levels of antigen in conjunction with costimulatory molecules. We performed this study to test the safety, feasibility and efficacy of autologous dendritic cell (DC)-derived exosomes (DEX) loaded with the MAGE tumor antigens in patients with non-small cell lung cancer (NSCLC). METHODS: This Phase I study enrolled HLA A2+ patients with pre-treated Stage IIIb (N = 4) and IV (N = 9) NSCLC with tumor expression of MAGE-A3 or A4. Patients underwent leukapheresis to generate DC from which DEX were produced and loaded with MAGE-A3, -A4, -A10, and MAGE-3DPO4 peptides. Patients received 4 doses of DEX at weekly intervals. RESULTS: Thirteen patients were enrolled and 9 completed therapy. Three formulations of DEX were evaluated; all were well tolerated with only grade 1-2 adverse events related to the use of DEX (injection site reactions (N = 8), flu like illness (N = 1), and peripheral arm pain (N = 1)). The time from the first dose of DEX until disease progression was 30 to 429+ days. Three patients had disease progression before the first DEX dose. Survival of patients after the first DEX dose was 52-665+ days. DTH reactivity against MAGE peptides was detected in 3/9 patients. Immune responses were detected in patients as follows: MAGE-specific T cell responses in 1/3, increased NK lytic activity in 2/4. CONCLUSION: Production of the DEX vaccine was feasible and DEX therapy was well tolerated in patients with advanced NSCLC. Some patients experienced long term stability of disease and activation of immune effectors.
Morse
Michael A
MA
Department of Medicine, Duke University Medical Center, Durham, NC, USA. michael.morse@duke.edu.
Garst
Jennifer
J
Osada
Takuya
T
Khan
Shubi
S
Hobeika
Amy
A
Clay
Timothy M
TM
Valente
Nancy
N
Shreeniwas
Revati
R
Sutton
Mary Ann
MA
Delcayre
Alain
A
Hsu
Di-Hwei
DH
Le Pecq
Jean-Bernard
JB
Lyerly
H Kim
HK
Blood. 1999 Dec 1;94(11):3791-9
10572093
J Immunol. 2001 Jan 15;166(2):868-76
11145662
Nat Med. 1998 May;4(5):594-600
9585234
Clin Cancer Res. 2003 Feb;9(2):657-62
12576432
J Cell Biol. 1999 Nov 1;147(3):599-610
10545503
J Cell Sci. 2000 Oct;113 Pt 19:3365-74
10984428
Biochem Cell Biol. 1992 Mar-Apr;70(3-4):179-90
1515120
J Immunol Methods. 2002 Dec 15;270(2):211-26
12379326
Nat Med. 2001 Mar;7(3):297-303
11231627
J Clin Oncol. 2004 Jan 15;22(2):330-53
14691125
Yale J Biol Med. 2002 Mar-Apr;75(2):95-101
12230314
J Cell Physiol. 2003 Jun;195(3):346-55
12704644
J Exp Med. 1996 Mar 1;183(3):1161-72
8642258
Lancet. 2002 Jul 27;360(9329):295-305
12147373
Lung Cancer. 2003 Jan;39(1):55-61
12499095
Nat Rev Immunol. 2002 Aug;2(8):569-79
12154376
J Immunol. 2004 Feb 15;172(4):2126-36
14764678
J Immunol. 1999 Aug 1;163(3):1274-81
10415024
J Immunol Methods. 2002 Aug 1;266(1-2):79-86
12133624
Int J Cancer. 1995 Jun 22;64(3):158-65
7622303
J Clin Oncol. 2000 Jun;18(12):2354-62
10856094
N Engl J Med. 2002 Jan 10;346(2):92-8
11784875
Cancer Res. 2000 Nov 15;60(22):6272-5
11103782
J Immunol. 2001 Jun 15;166(12):7309-18
11390481
Immunol Invest. 2000 May;29(2):149-62
10854184
Lung Cancer. 1998 May;20(2):117-25
9711530
Curr Opin Mol Ther. 2002 Aug;4(4):372-81
12222875
Nat Immunol. 2002 Dec;3(12):1156-62
12426563
J Immunol. 2000 Aug 1;165(3):1259-65
10903724
J Immunother. 2003 Sep-Oct;26(5):440-50
12973033